ERBB2 and breast cancer: Furthermore, CA was greater in triple negative and HER2 amplified subtypes (Fig. 2c); in general, estrogen/progesterone receptor-positive breast cancers have a more favorable prognosis than HER2 amplified or triple negative cancers [35].